A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.

被引：0

作者：

Stein, Anthony Selwyn

Jongen-Lavrencic, Mojca

Garciaz, Sylvain

Huls, Gerwin A.

Maiti, Abhishek

Boissel, Nicolas

De Botton, Stephane

Fleming, Shaun

Zwaan, C. Michel

de Leeuw, David C.

Desai, Pinkal

Arellano, Martha Lucia

Avigan, David

Langemeijer, Saskia

Jensen, Kyle A.

Wagenaar, Timothy

Mi, Gu

Abbadessa, Giovanni

Bajel, Ashish

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Erasmus MC, Rotterdam, Netherlands

[3] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France

[4] Univ Med Ctr Groningen, Groningen, Netherlands

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[6] Hop St Louis, Paris, France

[7] Inst Gustave Roussy, Paris, France

[8] Alfred Hlth, Melbourne, Australia

[9] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

[10] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[11] Weill Cornell Med, New York, NY USA

[12] Emory Univ, Atlanta, GA USA

[13] Beth Israel Deaconess Med Ctr, Boston, MA USA

[14] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[15] Sanofi, Cambridge, MA USA

[16] Peter MacCallum Canc Ctr, Melbourne, Australia

[17] Royal Melbourne Hosp, Melbourne, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7005

引用

页数：1

共 50 条

[1] First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High RiskMyelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics
Bajel, Ashish
Garciaz, Sylvain
Desai, Pinkal
Huls, Gerwin A.
Maiti, Abhishek
Jongen-Lavrencic, Mojca
Boissel, Nicolas
De Botton, Stephane
de Leeuw, David C.
Fleming, Shaun
Zwaan, C. Michel
Arellano, Martha
Avigan, David
Saultz, Jennifer N.
Mantzaris, Ioannis
Jensen, Kyle
Wagenaar, Timothy
Mi, Gu
Ziti-Ljajic, Samira
Draganov, Dobrin
Abbadessa, Giovanni
Stein, Anthony Selwyn
BLOOD, 2023, 142
[2] A First-in-Human Study of CD123 Natural Killer Cell Engager (NKCE) SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)
Stein, Anthony
Lavrencic, Mojca
Garciaz, Sylvain
Huls, Gerwin
Maiti, Abhishek
Boissel, Nicolas
Botton, Stephane
Fleming, Shaun
Zwaan, Michel
de Leeuw, David C.
Desai, Pinkal
Arellano, Martha
Avigan, David
Langemeijer, Saskia
Jensen, Kyle
Wagenaar, Timothy
Mi Gu
Abbadessa, Giovanni
Bajel, Ashish
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S3 - S4
[3] Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)
Jongen-Lavrencic, M.
Bajel, A.
Garciaz, S.
Maiti, A.
Fleming, S.
De Button, S.
Huls, G. A.
Jensen, K.
Ziti-Ljajic, S.
Draganov, D.
Rotolo, F.
Palu, C.
Courta, J.
Passe-Coutrin, W.
Traudtner, K.
Wagenaar, T.
Abbadessa, G.
Stein, A. Selwyn
ANNALS OF ONCOLOGY, 2023, 34 : S543 - S544
[4] An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
Stein, Anthony S.
Bajel, Ashish
Fleming, Shaun
Jongen-Lavrencic, Mojca
Garciaz, Sylvain
Maiti, Abhishek
Boissel, Nicolas
De Botton, Stephane
Huls, Gerwin A.
de Leeuw, David C.
Avigan, David
Jensen, Kyle
Demers, Brigitte
Wagenaar, Timothy
Mi, Gu
Ziti-Ljajic, Samira
Draganov, Dobrin
Abbadessa, Giovanni
Wei, Andrew H.
BLOOD, 2022, 140 : 7476 - 7477
[5] First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
Boyiadzis, Michael
Desai, Pinkal
Daskalakis, Nikki
Donnellan, William
Ferrante, Lucille
Goldberg, Jenna D.
Grunwald, Michael R.
Guttke, Christina
Li, Xiang
Perez-Simon, Jose Antonio
Salamero, Olga
Tucker, Trevor
Xu, Xiaoying
Yang, Jay
Pemmaraju, Naveen
Alonso-Dominguez, Juan Manuel
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (03): : 429 - 435
[6] An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.
Boissel, Nicolas
de Botton, Stephane
Thomas, Xavier G.
Rao, Ercole
Bonnevaux, Helene
Rubin-Carrez, Chantal
Guerif, Stephane
Beys, Eric
Gosselin, Alice
Bauchet, Anne-Laure
Novikov, Valery
Fernandes, Elma
Wiederschain, Dmitri
Palatinsky, Emanuel A.
Hsu, Karl
Fraenkel, Paula Goodman
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
Laurent Gauthier
Angela Virone-Oddos
Jochen Beninga
Benjamin Rossi
Céline Nicolazzi
Céline Amara
Audrey Blanchard-Alvarez
Nicolas Gourdin
Jacqueline Courta
Alexandra Basset
Magali Agnel
Franceline Guillot
Gwendoline Grondin
Hélène Bonnevaux
Anne-Laure Bauchet
Ariane Morel
Yannis Morel
Marielle Chiron
Eric Vivier
Nature Biotechnology, 2023, 41 : 1296 - 1306
[8] Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
Gauthier, Laurent
Virone-Oddos, Angela
Beninga, Jochen
Rossi, Benjamin
Nicolazzi, Celine
Amara, Celine
Blanchard-Alvarez, Audrey
Gourdin, Nicolas
Courta, Jacqueline
Basset, Alexandra
Agnel, Magali
Guillot, Franceline
Grondin, Gwendoline
Bonnevaux, Helene
Bauchet, Anne-Laure
Morel, Ariane
Morel, Yannis
Chiron, Marielle
Vivier, Eric
NATURE BIOTECHNOLOGY, 2023, 41 (09) : 1296 - +
[9] Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia
Shukla, Neerav
Sulis, Maria Luisa
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (09): : 830 - 832
[10] CD123 expression linked to high-risk disease in children with acute myeloid leukemia
不详
CANCER, 2022, 128 (07) : 1357 - 1358

← 1 2 3 4 5 →